Immunocodex is committed to designing novel tolerogenic mRNA vaccines which re-program immune cells, re-balance the immune system, and restore health in patients suffering from autoimmune diseases. Through the integration of key tolerance-inducing signals alongside disease-specific autoantigens, we engineer effective, targeted therapies for the treatment of disease, while limiting negative systemic side effects.

 

Through Immunocodex’s first-in-class platform approach, we can target numerous

immune-mediated diseases and pave the way towards better outcomes for so many patients.